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INTRODUCTION
Patients with long-standing and extensive ulcerative 
colitis （UC） exhibit increased incidence of colorectal 
neoplasia1,2）. The diagnosis of this condition at an early 
or precancerous stage is crucial 3 ,4）. The established 
method of surveillance is colonoscopy, but this is asso-
ciated with difficulty in discriminating UC-associated 
neoplasia from inflammatory or regenerative epitheli-
um5）. In order to improve the efficacy of surveillance, 
there is an urgent need for sensitive and specific 
markers to identify individuals at increased risk of 
neoplasia among patients with long-standing and ex-
tensive UC. In order to help predict colorectal neopla-
sia risk, we previously used immunohistochemical 
29
Received November 11, 2011；accepted November 29, 2011
Reprint requests to：Kazuhito Ichikawa MD, PhD.
Department of Surgical and Molecular 
Pathology, Dokkyo Medical University 
School of Medicine, 880 Kitakobayashi, Mibu, 
Shimotsuga, Tochigi 321-0293, Japan.
Dokkyo Journal of Medical Sciences
39（1）：29〜35，2012
Diagnostic Validity of DNMT-1 and 3b Immunoreactivity 
in Non-neoplastic Epithelium of UC Patients with and 
Without Neoplasia
Hiroyuki Tanaka1,2, Kazuhito Ichikawa1, Takahiro Fujimori1,  
Shinichiro Ohtake1, Yoshikazu Yasuda2
1Department of Surgical and Molecular Pathology, Dokkyo Medical University School of Medicine, 
2Department of Surgery, Jichi Medical University School of Medicine
SUMMARY
It is important to improve the efficacy of surveillance in UC patients with neoplasia.
In the present study, we assessed the cut-off value of expression of DNMT-1 and DNMT-3b expression 
in the non-neoplastic rectal epithelium of patients with long-standing and extensive UC. Sixty patients with 
long-standing and extensive UC paticipated in this study （30 with colorectal neoplasia and 30 without）. Im-
munohistochemical analysis was performed to determine the expression of DNMT-1 and 3b in non-neoplas-
tic rectal epithelium of UC patients without neoplasia, and in non-neoplastic rectal epithelium of UC patients 
with neoplasia. The level of immunoreactive DNMT-1 and DNMT-3b expression was determined as the 
percentage of positive cells relative to the total number of cells counted under high power magnification. 
DNMT-1 and 3b expression in non-neoplastic rectal epithelium of UC patients with neoplasia （0.57, range 
0.53-0.63）（0.32, range 0.18-0.67） was higher than in the non-neoplastic epithelium of UC patients without 
neoplasia （0.41, range 0.25-0.54, P＝.001）（0.0, range 0.0-0.13, P＜.001）. ROC curve analysis confirmed 
0.53 and 0.07 as the best DNMT-1 and DNMT-3b cut-off values for identifying individuals at increased 
risk of neoplasia （area under the curve＝0.798 and 0.842, respectively）. The cut-off value for DNMT-1 and 
DNMT-3b expression in non-neoplastic rectal epithelium is therefore an efficient predictor for the increased 
risk of UC-associated neoplasia．
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methods to show that the expression of DNA methyl-
transferase-1 （DNMT-1） progressively increased 
from the rectal epithelium of UC patients without neo-
plasia to non-neoplastic rectal epithelium of UC pa-
tients with neoplasia 6）. However, it remained unclear 
whether the determination of immunoreactive DNMT-
1 and 3b expression could be a useful predictor for col-
orectal neoplasia risk in UC patients. In the present 
study, we assessed the cut-off value of expression of 
DNMT-1 and DNMT-3b expression in the non-neo-
plastic rectal epithelium of patients with long-standing 
and extensive UC.
MATERIALS AND METHODS
Patients and samples
Sixty UC patients participated in the study：30 （16 
men, 14 women） with colorectal neoplasia and 30 （20 
men, 10 women） without. We studied the non-neoplas-
tic rectal epithelium of each patient. All patients were 
diagnosed at Dokkyo Medical University School of 
Medicine and its associated institutes between 2000 
and 2009 . The clinicopathological features of our UC 
patients are shown in Table 1. The mean （±SD） age 
of the UC patients with neoplasia was 48.6±10.4 years 
（range 26-74）, and that of the UC patients without 
neoplasia was 46 .9±7.5 years （range 33-59）. Mean 
（±SD） duration of disease in the UC patients with 
neoplasia was 16.4±5.5 years （range 7-29）, while that 
in the UC patients without neoplasia was 18 .2±7 .4 
years （range 10-36）. There were no significant differ-
ences in age, sex, disease duration, or disease extent, 
between UC patients with, and without neoplasia. His-
tologically, we confirmed that all of the 60 non-neo-
plastic samples from UC patients with and without 
neoplasia were negative for neoplasia in accordance 
with the Riddell classification of gastrointestinal epithe-
lial neoplasia7）. Histological evaluations were confirmed 
by two experienced gastrointestinal pathologists （TF, 
SF） and a gastrointestinal surgeon （HT）. All UC pa-
tients without neoplasia were diagnosed as neoplasia-
free via endoscopy and histological assessments 
throughout periodic surveillance colonoscopy on the 
basis of multiple-step biopsy samples. The Ethics Com-
mittee of Dokkyo Medical University School of Medi-
cine approved all protocols, and informed consent for 
tissue procurement was obtained from all the patients.
Immunohistochemical analysis of DNMT-1, and 
DNMT-3b protein
Immunohistochemical staining for DNMT-1 and 3b 
was performed universal immunoperoxidase polymer 
method as described previously6）. In brief, sections 
（4 mm thick） placed on silane-coated slides were de-
paraffinized, rehydrated, and then pretreated with 3％ 
H2O2 in methanol for 5 min at room temperature to 
quench endogenous peroxidase activity. The sections 
were doused in 0 .01 M citrate buffer （pH 7 .0） and 
heated to 95℃ in a microwave oven （MI-77, Azumaya, 
Tokyo, Japan；400 W） for 40 min to facilitate antigen 
retrieval. The sections were incubated with 1％ bovine 
serum albumin in phosphate-buffered saline （PBS） for 
30 min, and then with a goat anti-human polyclonal 
DNMT-1 antibody （N16, dilution 1：50；Santa Cruz 
Biotechnology, Santa Cruz, Calif., USA） or anti-mouse 
DNMT3b antibody （IMG-184A；IMGENEX, San Di-
ego, CA, USA；dilution 1：20） for 30 min. Thereafter, 
the sections were incubated with Envison＋/HRP Sys-
tem （Dako, Carpinteria, CA, USA） for 60 min, and 
washed with PBS. Finally, they were incubated in 
3 ,3 ’-diaminobenzidine tetrahydrochloride with 0 .05％ 
H2O2 for 3 min and then counterstained with Carazzi’s 
hematoxylin. The immunoreactivity of DNMT-1 and 
DNMT-3b was assessed in areas showing the highest 
density of cells with positively staining nuclei. The lev-
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Table 1　Clinicopathological characteristics of UC patients with and without neoplasia
UC with
neoplasia （n＝30）
UC without
neoplasia （n＝30）
Mean age at study, years 48.6±10.4 46.9±7.5
Male/Female 16/14 20/10
Mean disease duration of UC, years 16.4±5.5 18.2±7.4
Disease extent （total/left） 26/4 24/6
DNA Methyltransferase Expression in UC
el of immunoreactive DNMT-1 and DNMT-3b expres-
sion is given as the percentage of positive cells relative 
to the total number of cells counted under high power 
magnification6）.
Statistical analysis
JMP 8 statistical software （SAS Institute Inc, Cary, 
NC） was used for all analyses. Continuous variables 
were expressed as mean±standard deviation （SD）, or, 
where indicated, median and interquartile range （IRQ）
. For continuous variables, 2-group comparisons were 
performed with the parametric 2-sample t test or with 
the nonparametric Mann-Whitney U test. For all tests, 
differences of P＜0.05 were considered statistically sig-
nificant；all P values were two-sided. A receiver oper-
ating characteristics （ROC） curve was generated and 
the area under the curve calculated to determine the 
best discriminating DNMT-1 and DNMT-3b expres-
sion of non-neoplastic epithelium and neoplastic epi-
thelium. Sensitivity, specificity, positive and negative 
predictive values and likelihood ratios, and accuracy 
were calculated with standard formulas.
RESULT
Immunohistochemical staining was carried out upon 
non-neoplastic rectal epithelium samples from 30 UC 
patients with neoplasia, and on non-neoplastic rectal 
epithelium samples from 30 UC patients without neo-
plasia. We were able to evaluate 28 non-neoplastic rec-
tal epithelia from UC patients with neoplasia and 15 
non-neoplastic rectal epithelia from 30 UC patients 
without. DNMT-1 and DNMT-3b expression levels in 
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Fig. 1-d　 Non-neoplastic epithelium of UC patients 
with neoplasia （DNMT-3b）.
Fig. 1-a　 Non-neoplastic epithelium of UC patients 
without neoplasia （DNMT-1） Fig. 1-b　 Non-neoplastic epithelium of UC patients 
with neoplasia （DNMT-1） 
Fig. 1-c　 Non-neoplastic epithelium of UC patients 
without neoplasia （DNMT-3b）.
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non-neoplastic rectal epithelium from UC patients with 
and without are shown in Figure 1 . The median and 
interquartile （IQR） of immunoreactive DNMT-1 ex-
pression were 0.41 （0.25-0.54） and 0.57 （0.53-0.63） in 
non-neoplastic rectal epithelium of UC patients with-
out and with neoplasia, respectively. Non-neoplastic 
rectal epithelium of UC patients without and with neo-
plasia differed significantly in the level of immunostain-
ing for DNMT1 expression （P＝0.001）（Figure 2）. 
The median and interquartile （IQR） of immunoreac-
tive DNMT-3b expression were 0.00 （0.00-0.13） and 
0.32 （0.18-0.67） in non-neoplastic rectal epithelium of 
UC patients without and with neoplasia. Non-neoplas-
tic rectal epithelium of UC patients without and with 
neoplasia differed significantly in the level of immunos-
taining for DNMT3b expression （P＜0.001）（Figure 2）
. ROC curve analysis confirmed 0 .53 and 0 .07 as the 
best DNMT-1 and DNMT-3b cut-off value for identi-
fying individuals at increased risk of neoplasia （area 
under the curve＝0.798 and 0.842 respectively）. In the 
diagnostic validity of cut-off value of immunoreactive 
DNMT-1 expression, sensitivity of the diagnostic test 
was 80.0％, and the specificity was 75.0％, the positive 
predictive value 63 .2％ and the negative predictive 
value 87.5％. The positive likelihood ratio was 3.20 and 
the negative likelihood ratio 0 .31 . The accuracy was 
76.7％ （Table 2）. In the diagnostic validity of cut-off 
value of immunoreactive DNMT-3b expression, sensi-
tivity of the diagnostic test was 86.7％, specificity 75.0
％, the positive predictive value 65.0％ and the nega-
tive predictive value 91.3％. The positive likelihood ra-
tio was 3.44 and the negative likelihood ratio 0.28. The 
accuracy was 79.1％ （Table 3）.
DISCUSSION
In the present study, we have shown that the ex-
pression of DNA methyltransferase-1 and 3b in non-
neoplastic rectal epithelium was higher in patients 
with neoplasia than in those without. We also deter-
mined the cut-off value for DNA methyltransferase-1 
and 3b expression, and examined whether the cut-off 
value may be useful in identifying individuals at in-
creased risk of neoplasia. Immunohistochemistry 
proved to be a sufficient method with which to deter-
mine DNMT-1 and 3b expression and tissues differed 
significantly in terms of DNMT-1 and 3b immunoreac-
tivity. In terms of diagnostic validity of the best 
DNMT-1 and DNMT-3b cut-off values, we deter-
mined that the positive likelihood ratio was 3.20, 3.44, 
its ratio is equivalent. Since Warren was the first to 
suggest that UC-associated dysplasia was a precursor 
of colitic cancer in UC patients8）. Sinece then UC-asso-
ciated dysplasia has been observed in UC patients. In 
western countries, recommendations are to employ pe-
riodic surveillance using colonoscopy on the basis of 
multiple-step biopsy9,10）. Issa et al. reported that first 
reported that age-related methylated genes were 
highly methylated in non-neoplastic epithelium from 
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Fig. 2　Level of immunoreactive DNMT-1 and 3b expression in non-neoplastic rectal epithelium.
DNA Methyltransferase Expression in UC
UC patients with high-grade dysplasia/cancer, com-
pared with compared with non-neoplastic epithelium 
from UC patients without neoplasia 11 ,12）. In our own 
previous studies, we investigated the methylation sta-
tus of the ESR-1 gene using the combined bisulfite re-
striction analysis method in surveilance. ESR-1 gene 
was highly methylated in non-neoplastic epithelium 
from UC patients with high-grade dysplasia/cancer 
compared with non-neoplastic epithelium from UC pa-
tients without neoplasia 13 ,14）. Other reports have re-
vealed that RUNX-3, MINT-1, ESR-1, N-33 were as-
sociated with high methylation levels15,16）. However the 
combined bisulfite restriction analysis method for in-
vestigating gene methylation status of gene is very 
time consuming, and it is therefore very difficult to en-
visage how this might be applied clinically. Therefore, 
in the present study we investigated whether immuno-
histochemistry could be a more viable technique for 
clinical application. Using this method, we found that 
DNA methyltransferase-1 was highly methylated in 
non-neoplastic epithelia from UC patients with high-
grade dysplasia/cancer compared with non-neoplastic 
epithelium from UC patients without neoplasia 6）. We 
therefore consider that this methodology could be ap-
plied clinically but highlight the need to determine a 
cut-off value for surveillance. To this end, we also at-
tempted to determine a cut-off value for DNMT-1 and 
3b immunoreactivity. The assessment of DNMT-1 and 
3b immunoreactivity therefore represents a cut-off 
value for predicting the risk of colorectal neoplasia in 
UC patients. If we assess DNMT-1 and 3b immnreac-
tivity at a timepoint close to the definitive diagnosis, 
we will be able to increase the cut-off value in order 
to increase specificity. ROC curve was generated in or-
der to determine the best sensitivity and specificity for 
predicting colorectal neoplasia risk in UC patients. 
Consequently, the best cut-off values for DNMT-1 and 
DNMT-3b immunoreactivity were 0 .53 and 0 .07 re-
spectively. Previously, DNMT positive cells in more 
than 20％ of the cells exhibiting nuclear immunostain-
ing. Methods for assessing DNMT-3b immunoreactivi-
ty have included determination of the specific strength 
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Table 3　 Diagnostic validity of DNMT-3b immunoreactivity in non-
neoplastic epithelium of UC patients with and without neoplasia.
DNMT-3b immunoreactivity Total
Positive Negative
Non-neoplastic epithelium  
with neoplasia
13 2 15
Non-neoplastic epithelium 
without neoplasia
7 21 28
Sensitivity 86.7％, specificity 75.0％, the positive predictive value 65.0％ and 
the negative predictive value 91.3％, the positive likelihood ratio 3.44 and the 
negative likelihood ratio 0.28, the accuracy 79.1％.
Table 2　 Diagnostic validity of DNMT-1 immunoreactivity in non-neoplastic 
epithelium of UC patients with and without neoplasia.
DNMT-1 immunoreactivity Total
Positive Negative
Non-neoplastic epithelium  
with neoplasia
12 3 15
Non-neoplastic epithelium 
without neoplasia
7 21 28
Sensitivity 80.0％, specificity 75.0％, the positive predictive value 63.2％ and 
the negative predictive value 87.5％, the positive likelihood ratio 3.20, the 
negative likelihood ratio 0.31. the accuracy 76.7％
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of staining17〜19）. Several study have assessed the neo-
plastic epithelium using such methodology and have 
examined the relationship between DNMT expression 
and recurrence, and between DNMT expression and 
prognosis. The specific aim of this study was to evalu-
ate the assessment DNMT-1 and 3b immunoreactivity 
as a means of predicting the risk of colorectal neopla-
sia in UC patients. However, earlier methods have re-
ported difficulty in distinguishing UC patients with 
neoplasia from UC patients without neoplasia. There-
fore, our ROC analysis was important in distinguishing 
UC patients with neoplasia from UC patients without 
neoplasia. DNMT-1 and 3b immunoreactivity proved 
to be very useful in involved remains to be fully eluci-
dated. Futher studies will therefore be required to 
clarify the mechanisms involed. Aberrant gene methy-
lation patterns arising in a wide range of colorectal epi-
thelial cells in UC patients implies that abnormal meth-
ylation may be one underlying aspect of colitis-
associated tumorigenesis. Accordingly, it is important 
for future studies to elucidate the precise relationship 
between aberrant gene methylation and colitis-associ-
ated tumorigenesis. In summary, the cut-off value of 
DNMT-1 and 3b immunoreactivity in non-neoplastic 
rectal epithelia was considerd as a useful factor for dif-
ferential diagnosis in the prediction of colorectal neo-
plasia risk in UC patients. We also concluded that it is 
reasonable for a new simple surveillance protocol to 
assess the cut-off value of expression of DNMT-1 and 
DNMT-3b immunoreactivity in non-neoplastic rectal 
epithelium in patients with long-standing and exten-
sive UC.
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